Get Ready for AUA 2025 in Las Vegas!

Attention urology enthusiasts! The American Urological Association (AUA) is gearing up for an electrifying annual meeting in the dazzling city of Las Vegas from April 26 to 29, 2025. The event, hosted at the luxurious Venetian Las Vegas, promises to be packed with cutting-edge scientific presentations, engaging lectures, and heated Crossfire Debates. Plus, don’t miss the AUA Innovation Nexus on April 25, showcasing groundbreaking advancements in urology.

High-Risk Bladder Cancer Breakthroughs!

This year’s spotlight will shine on key presentations in urologic oncology. One of the most anticipated talks will be by Dr. Neal D. Shore, who will unveil groundbreaking data on sasanlimab combined with Bacillus Calmette-Guerin (BCG) for high-risk non-muscle-invasive bladder cancer. Prior phase 3 trial results suggest that this new combination significantly enhances event-free survival compared to BCG alone.

BOND-003: A Game-Changer for IC Patients!

Dr. Mark D. Tyson II from the Mayo Clinic will take the stage to share findings from the intriguing BOND-003 trial. With a complete response (CR) rate soaring to 74.5%, this single-arm study of cretostimogene grenadenorepvec for BCG-unresponsive conditions shows promise for transforming treatment strategies.

Innovative Solutions with TAR-200!

Two presentations on the innovative TAR-200 system will highlight its effectiveness against BCG-unresponsive bladder cancer. Dr. Joseph Jacob will present data on the one-year durability of TAR-200, while Dr. Felix Guerrero-Ramos will reveal promising results from cohort 4 of the SunRISe-1 trial, showing a CR rate of 83.5%!

Surgery vs. Bladder-Sparing Therapy: The Big Reveal!

In a compelling study, Dr. John L. Gore will present pivotal results comparing radical cystectomy with bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer, providing vital insights on treatment options.

Prostate Cancer Trial Results You Can’t Miss!

Dr. Michael R. Abern will disclose exciting results from a randomized phase 3 trial evaluating CAN-2409 combined with standard external beam radiation for newly diagnosed localized prostate cancer. The findings suggest a significant boost in disease-free survival, promising a new ray of hope for patients.

Stay Tuned for More Updates!

The AUA 2025 meeting is set to be a landmark event in urologic oncology, with presentations that could shift the treatment landscape considerably. Follow Urology Times for live coverage and updates from this thrilling event!